XML 43 R26.htm IDEA: XBRL DOCUMENT v3.25.1

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2024

Summary of Significant Accounting Policies [Abstract]

Inventory Stated at Cost, Net of Reserve

Inventory stated at cost, consisted of the following as of December 31:

		2024				2023
Materials		$	1,308,863				367,934
Work in progress			982,630				128,993
Finished goods			754,830				170,191
Inventory		$	3,046,323				667,118

Other Assets

The Company has included these amounts on the accompanying balance sheets as follows as of December 31:

		2024				2023
Prepaid and other current assets		$	315,897				224,000
Other long-term assets			714,912				704,234
Research tax credits available to the Company		$	1,030,809				928,234

Estimated Useful Lives of Assets

Depreciation and amortization are computed using the straight‑line method over estimated useful lives of assets as follows:

Leasehold improvements	Shorter of lease term(s) or useful life
Office equipment	5 years
Furniture and fixtures	7 years
Machinery and equipment	5 to 7 years

Intangible Assets

Intangible assets consist of the following as of December 31:

		2024				2023
Cost		$	1,755,009				1,668,951
Accumulated amortization			(1,689,091	)			(1,668,951	)
Net book value		$	65,918				—

Accrued Expenses

Accrued expenses consisted of the following as of December 31:

		2024				2023
Incentive and other compensation costs		$	650,768				1,082,606
Clinical trial costs			354,762				276,141
Director fees			70,000				60,210
Franchise taxes			—				12,160
Other			75,519				13,179
Accrued expenses		$	1,151,049				1,444,296

Clinical Holdback Liability

The following table shows the activity within the clinical holdback liability accounts for the year ended December 31, 2024:

Balance at December 31, 2023		$	120,235
Clinical holdback retained			19,452
Clinical holdback paid			(11,495	)
Balance at December 31, 2024		$	128,192
Less: clinical holdback - current portion			(88,581	)
Clinical holdback - long-term portion		$	39,611

The following table shows the activity within the clinical holdback liability accounts for the year ended December 31, 2023:

Balance at December 31, 2022		$	141,864
Clinical holdback retained			5,900
Clinical holdback paid			(27,529	)
Balance at December 31, 2023		$	120,235
Less: clinical holdback - current portion			(65,300	)
Clinical holdback - long-term portion		$	54,935

Sales by Geographic Region

The following table summarizes the Company’s sales by geographic region for the years ending December 31:

Primary geographical markets		2024				2023
U.S.		$	1,073,508				1,013,925
International			555,600				58,045
Total		$	1,629,108				1,071,970

X

- Definition

Tabular disclosure of clinical holdback liability account.

+ References

No definition available.

+ Details

Name:	femy_ScheduleOfClinicalHoldbackLiabilityAccountTableTextBlock
Namespace Prefix:	femy_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_AccountingPoliciesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-SubTopic 10
-Topic 360
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1

+ Details

Name:	us-gaap_PropertyPlantAndEquipmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

+ Details

Name:	us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the components of accrued liabilities.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

+ Details

Name:	us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483489/210-10-50-1

+ Details

Name:	us-gaap_ScheduleOfInventoryCurrentTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfOtherAssetsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration